Quick answers
- What is Tafluprost used for?
- The FDA-approved label (Zioptan, Thea Pharma Inc., April 23, 2026) says: “ZIOPTAN® is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ZIOPTAN is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Tafluprost have a boxed warning?
- No. None of the 5 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Tafluprost?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Tafluprost been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Tafluprost?
- 5 companies list prescription products of Tafluprost in the FDA NDC Directory, including Ingenus Pharmaceuticals, LLC, Prasco Laboratories and Sandoz Inc.
What Tafluprost is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ZIOPTAN® is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ZIOPTAN is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
— FDA label: Zioptan, Thea Pharma Inc., effective April 23, 2026. Read the full label on DailyMed →
The FDA has 5 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 5 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Solution/ drops |
|---|---|
| Route | Ophthalmic |
| Prescription products | 5 in the FDA NDC Directory |
| Brand names | Zioptan |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| tafluprost 0.0045 mg/0.3 mL solution/ drops | Generic | $2.35 per unit |
| tafluprost 0.015 mg/mL solution/ drops | Generic | $2.35 per unit |
| tafluprost 0.015 mg/mL solution/ drops | Brand: Zioptan | $8.48 per unit |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Ingenus Pharmaceuticals, LLC1 product
- Prasco Laboratories1 product
- Sandoz Inc1 product
- Micro Labs Limited1 product
- Thea Pharma Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA202514 ZIOPTAN | Thea Pharma | February 10, 2012 | 5, latest February 25, 2026 2026: Labeling · 2015: Manufacturing (CMC) · 2015: Labeling |
Generic approvals (3)
- ANDA209051Micro Labs · August 19, 2019
- ANDA209040Sandoz · January 28, 2022
- ANDA218002Ingenus Pharms LLC · April 5, 2024
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1244611, 1244616 |
|---|---|
| SPL set ID of the quoted label | db529b54-2ac7-4020-9791-7333bbe6c90f |
| FDA labels (SPL) | 5 |
| FDA applications | NDA202514, 3 ANDA |
| Active ingredients (FDA) | TAFLUPROST |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Zioptan, Thea Pharma Inc., effective April 23, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →